On Sept. 1, Gilead struck a development deal for an immuno-oncology asset—the value of which spoke volumes about the industry’s enthusiasm for emerging immune targets for treating cancer.
https://www.fiercepharma.com/pharma/biopharma-nurtures-next-generation-immuno-oncology-targets